First Week Of XON February 2015 Options Trading
at The Street - Wed Dec 24, 10:57AM CST
Investors in Intrexon Corp saw new options become available this week, for the February 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XON options chain for the new February 2015 contracts and identified...
XON: 26.19 (+0.67)
Oragenics, Inc. to Explore Strategic Alternatives for its OTC Probiotic Products Business
Business Wire - Mon Dec 22, 3:54PM CST
Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT - OGEN) has announced today that its board of directors has authorized the exploration of strategic alternatives with respect to the Company's over-the counter (OTC) probiotic business. These alternatives could include joint ventures, strategic partnerships or alliances, a sale of the OTC probiotic products business or other possible transactions.
XON: 26.19 (+0.67), OGEN: 0.90 (-0.07)
Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection
PR Newswire - Mon Dec 22, 5:58AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1a clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 1.46 (-0.07), XON: 26.19 (+0.67)
Cramer's Mad Money - 13 Things To Watch In The Week Ahead (12/12/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 14, 5:42AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 12. 13 Things to Watch in the Week Ahead: Honeywell (NYSE: HON ), Verifone (NYSE: PAY ), Darden (NYSE: DRI ), 3M (NYSE: MMM ), FedEX (NYSE: FDX ),...
JOY: 48.23 (+0.31), FDX: 176.42 (-0.52), MMM: 166.96 (+0.09), LBRDA: 50.88 (-0.37), NKE: 96.29 (+0.32), HON: 101.96 (-0.02), BBRY: 10.67 (-0.13), CHTR: 167.46 (-0.31), XON: 26.19 (+0.67), RMTI: 8.41 (-0.07), ORCL: 46.23 (+0.22), DRI: 58.42 (-0.09), KMX: 67.61 (-0.15), PAYX: 47.06 (-0.31), ISIS: 59.49 (+1.88), RHT: 70.92 (+0.47), JDSU: 14.01 (+0.13), AGIO: 109.67 (+2.45), FL: 55.31 (+0.09), PAY: 37.55 (-0.83), REGN: 400.12 (+6.07), PII: 150.40 (+0.38)
Jim Cramer's Top Stock Picks: DRI XON PII
at The Street - Sat Dec 13, 5:00AM CST
Cramer says if Darden Restaurant shares fall Monday, buy before it reports earnings Tuesday.
XON: 26.19 (+0.67), PII: 150.40 (+0.38), DRI: 58.42 (-0.09)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 166.96 (+0.09), SWX: 61.24 (+0.67), HON: 101.96 (-0.02), NKE: 96.29 (+0.32), CHTR: 167.46 (-0.31), BBRY: 10.67 (-0.13), XON: 26.19 (+0.67), RMTI: 8.41 (-0.07), KMX: 67.61 (-0.15), MEMP: 14.46 (-0.31), ACAD: 30.95 (+0.78), PAYX: 47.06 (-0.31), AGU: 95.91 (+0.20), TRUE: 23.50 (+0.31), LOW: 67.51 (-0.43), TWTR: 37.61 (+0.04), REGN: 400.12 (+6.07), JOY: 48.23 (+0.31), FDX: 176.42 (-0.52), LBRDA: 50.88 (-0.37), FINL: 22.79 (+0.17), ORCL: 46.23 (+0.22), DRI: 58.42 (-0.09), BAX: 74.45 (-0.04), RHT: 70.92 (+0.47), AGIO: 109.67 (+2.45), PAY: 37.55 (-0.83), PG: 93.14 (-0.15)
Strong On High Relative Volume: Intrexon (XON)
at The Street - Thu Dec 11, 9:01AM CST
Trade-Ideas LLC identified Intrexon (XON) as a strong on high relative volume candidate
XON: 26.19 (+0.67)
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 16.23 (-0.23), ARWR: 6.35 (+0.07), SGMO: 14.20 (+0.14), XON: 26.19 (+0.67), RBIO: ()
Intrexon Announces the Appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology
PR Newswire - Thu Dec 04, 8:00AM CST
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology. Dr. Emtage will focus on further advancing the Company's oncology and immunology platforms to bring the next generation of cellular-based solutions that overcome the limitations of current treatments and address the most challenging malignancies.
XON: 26.19 (+0.67)
ZIOPHARM and Intrexon Present Clinical and Preclinical Data From Immuno-Oncology Programs at AACR Tumor Immunology and Immunotherapy Meeting
GlobeNewswire - Wed Dec 03, 11:30AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of clinical and preclinical studies from their immuno-oncology programs at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting taking place December 1-4, 2014 in Orlando, Florida. Presentations include:
ZIOP: 4.76 (+0.07), XON: 26.19 (+0.67)
Global Synthetic Biology Market 2014-2018: Market to Reach $5.6 Billion in 2018, Growing at a CAGR of 24%
M2 - Tue Dec 02, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/4g44dp/synthetic_biology) has announced the addition of the "Synthetic Biology Market by Tool, Technology, Application - Global Forecast to 2018" report to their offering. The global synthetic biology market is expected to reach $5,630.4 million in 2018 from $1,923.1 million in 2013, growing at a CAGR of 24% The synthetic biology market is highly competitive with a large number of players, including both big and small players, operating in this market. Synthetic biology is an emerging area of research and is broadly described as the design and construction of novel organisms or devices, artificial biological pathways, and the redesign of existing natural biological systems. The global synthetic biology market is segmented on the basis of tools, technologies, applications, and regions. On the basis of tools, the market is categorized into Xeno-nucleic acids, chassis organisms, oligonucleotides, enzymes, and cloning and assembly kits. The oligonucleotides segment is expected to account for the largest share of the synthetic biology market, by tool. However, the cloning and assembly kits segment is expected to grow at the fastest rate in the market, by tool. On the basis of technologies, the synthetic biology market is segmented into enabling and enabled technologies. Enabling technologies account is the largest and fastest-growing segment of the market, by technology. On the basis of applications, the synthetic biology market is segmented into environmental, medical, and industrial applications. Medical application is the largest (2013) and fastest-growing segment of the market, by application. The key factors that are expected to spur the growth of this market are increasing R&D expenditure in pharmaceutical and biotechnology companies, growing demand for synthetic genes, rising production of genetically modified crops, and incessantly rising funding in this field. However, ethical and social issues such as biosafety and biosecurity of synthetic biology are hindering the growth of this market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Industry Speaks 6 Market Overview 7 Industry Insights 8 Synthetic Biology Market, By Tool 9 Market, By Technology 10 Market, By Application 11 Synthetic Biology Market, By Geography 12 Competitive Landscape 13 Company Profiles - Amyris, Inc. - Dupont - Genscript USA, Inc. - Integrated Dna Technologies (IDT), Inc. - Intrexon Corporation - New England Biolabs, Inc. - Novozymes - Royal DSM N.V. - Synthetic Genomics, Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/4g...ic_biology
AMRS: 2.16 (-0.02), XON: 26.19 (+0.67)
Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection
PR Newswire - Tue Dec 02, 7:04AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1a clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 1.46 (-0.07), XON: 26.19 (+0.67)
Technical Snapshot on Biotech Stocks - Keryx Biopharma, Dyax, Mast Therapeutics, Cubist Pharma, and Intrexon
PR Newswire - Mon Dec 01, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Intrexon Corporation (NYSE: XON). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 28, 2014, the NASDAQ Composite ended at 4,791.63, up 0.09%, the Dow Jones Industrial Average finished the day flat at 17,828.24, and the S&P 500 closed at 2,067.56, down 0.25%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 803.65, up 0.58%, with the index also advancing 8.95% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (+0.01), MSTX: 0.46 (unch), CBST: 100.29 (-0.09), XON: 26.19 (+0.67), DYAX: 14.13 (+0.30), KERX: 14.00 (+0.20)
Can Biotech Save Natural Gas Producers Billions in Flaring Costs?
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Nov 29, 3:00PM CST
A lack of pipelines in McKenzie County, N.D., forced the Orvis State well on the Evanson family farm to flare gas in 2013. Image source: Tim Evanson/ Flickr . The energy boom produced by shale formations across the United States has led to many...
CLR: 38.78 (-1.48), AMRS: 2.16 (-0.02), XON: 26.19 (+0.67)
BioPop Offers Bioluminescent Dino Pet Gift Option for Holiday Gifting
PR Newswire - Wed Nov 26, 9:16AM CST
Biological & Popular Culture, Inc. (BioPop), a company dedicated to creating "living art" concepts, offers consumers a perfect way to gift the Dino Pet to friends and family this holiday season. The Dino Pet is a living toy filled with photosynthetic plankton (also known as dinoflagellates) that glow a brilliant blue at night when you interact with them. Because wrapping a living organism is always a risky endeavor, the Dino Pet Gift Option includes the Dino Pet micro-aquarium and a "Fill'er Up" coupon in place of the dinoflagellates, so shoppers have the option of wrapping and storing the gift without fear of harming it. As part of the Gift Option, recipients can redeem the coupon for the dinoflagellates on BioPop's website and receive the living component directly, ensuring a healthy arrival, with no extra cost.
XON: 26.19 (+0.67)
Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection
PR Newswire - Mon Nov 24, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that its Investigational New Drug (IND) application which was submitted to the U.S. Food and Drug Administration (FDA) in October will be proceeding into clinical trials for the development of the Company's oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end.
SYN: 1.46 (-0.07), XON: 26.19 (+0.67)
Tracking Dan Loeb's Third Point Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 24, 1:26AM CST
FNSR: 19.75 (+0.07), ROP: 159.75 (+0.21), ENR: 132.20 (-0.04), CTXS: 64.48 (-0.19), ENPH: 14.38 (-0.02), AAL: 51.43 (+1.22), IACI: 61.82 (+0.63), WMB: 45.35 (-0.38), DG: 69.86 (+0.31), ABBV: 66.21 (+1.86), TMUS: 26.67 (+0.07), MC: 35.26 (+0.09), FDX: 176.42 (-0.52), RAX: 48.24 (+0.45), LNG: 71.64 (-0.12), TAP: 76.25 (-0.56), STZ: 100.09 (+0.95), YPF: 26.82 (-0.62), FDO: 79.14 (-0.01), AZN: 70.44 (+0.26), AIG: 56.28 (-0.16), DOW: 46.01 (+0.03), BID: 43.31 (+0.01), ASH: 119.40 (-0.48), ACT: 254.20 (-1.68), LBTYK: 49.10 (+0.05), CCK: 51.98 (-0.33), ALLY: 23.87 (-0.02), XON: 26.19 (+0.67), CCE: 45.10 (-0.23), BIOF: 7.28 (+0.01), AGN: 210.12 (+0.95), T: 33.96 (-0.07), ST: 53.70 (+0.16), EBAY: 57.10 (-0.12), LBTYA: 50.76 (-0.02), S: 4.19 (-0.05), SHPG: 209.29 (+0.07), WAG: 76.67 (+0.16), APC: 83.08 (-1.16), HRB: 33.72 (-0.08), BUD: 115.51 (+0.09), HTZ: 24.38 (-0.09), AMGN: 160.67 (+3.15), FMC: 57.74 (-0.18), MAS: 25.17 (-0.14), DISH: 72.63 (+0.54), EQT: 77.44 (-0.97), BBBY: 75.50 (-0.08), PH: 130.85 (-0.21), CF: 275.49 (-3.16), SUNE: 19.50 (+0.01), FLT: 149.17 (-0.93), VZ: 47.67 (unch), AVGO: 100.72 (-0.06), BABA: 105.95 (+0.43)
Tracking David Einhorn's Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 3:10AM CST
CNX: 34.95 (-0.09), TERP: 29.40 (-0.09), TLMR: 14.16 (+0.07), VOYA: 43.00 (+0.09), DNOW: 27.42 (-0.47), RBS: 12.31 (+0.14), AET: 89.59 (+0.14), NOK: 8.09 (+0.01), NOV: 66.18 (-0.30), AER: 39.40 (+0.26), CSC: 64.36 (+0.24), TPX: 54.98 (-0.15), CLNY: 24.27 (-0.16), CFG: 25.51 (+0.07), IACI: 61.82 (+0.63), SPR: 43.28 (-0.07), SYF: 30.11 (+0.11), GDX: 17.77 (+0.47), TIME: 24.10 (-0.06), MU: 34.91 (-0.06), TTWO: 28.60 (+0.18), BWC: 30.30 (-0.16), FSC: 8.08 (+0.01), CVEO: 8.01 (-0.56), BAGL: 20.23 (-0.01), DOX: 47.53 (+0.03), NRF: 17.54 (-0.15), GE: 25.83 (-0.05), LBTYK: 49.10 (+0.05), MDR: 2.78 (+0.01), URS: 54.20 (unch), GMCR: 137.65 (+1.10), XON: 26.19 (+0.67), TWX: 85.58 (-0.20), BIOF: 7.28 (+0.01), OIS: 49.01 (-0.10), KMT: 36.16 (-0.20), LBTYA: 50.76 (-0.02), FCB: 24.72 (-0.14), EMC: 30.69 (+0.14), ACM: 30.46 (+0.06), BP: 38.95 (-0.17), AAPL: 112.01 (-0.53), APC: 83.08 (-1.16), AGNC: 22.14 (-0.08), IPG: 20.50 (-0.06), VOD: 34.65 (-0.05), GLRE: 33.39 (+0.28), CI: 104.23 (-0.08), LRCX: 81.13 (-0.44), MRVL: 14.33 (+0.01), SUNE: 19.50 (+0.01), CONN: 18.23 (+1.23), NSAM: 22.38 (+0.15), CHMT: 24.69 (+0.18), ONNN: 10.22 (+0.05)
Can the Rally in Intrexon (XON) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 7:46AM CST
Can the Rally in Intrexon (XON) Shares Continue?
XON: 26.19 (+0.67)
Fibrocell Science Announces IND Allowed to Proceed to Develop New Treatment for Wounded Warrior Amputees to Prevent Stump Skin Diseases
GlobeNewswire - Tue Nov 18, 7:40AM CST
Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced the U.S. Food and Drug Administration is allowing the company's investigational new drug (IND) application to proceed for developing a new treatment for amputee stump skin to prevent skin diseases that lead to prosthesis abandonment.
FCSC: 2.38 (+0.04), XON: 26.19 (+0.67)